OverviewThis discussion board is aligned with the module objective “Demonstrate community assessments and apply the principles of epidemiology.” As part of the discussion you will:Review the concepts of epidemiology in disease control and prevention (p. 70-78).Apply ecosocial epidemiology paradigm (macro-level) to one of your chosen diagnosis from module 1 written assignment (p.72).Your initial post must be posted before you can view and respond to colleagues, must contain minimum of two (2) references, in addition to examples from your personal experiences to augment the topic. The goal is to make your post interesting and engaging so others will want to read/respond to it. Synthesize and summarize from your resources in order to avoid the use of direct quotes, which can often be dry and boring. No direct quotes are allowed in the discussion board posts.References:Initial Post: Minimum of two (2) total references: one (1) from required course materials and one (1) from peer-reviewed references..Words LimitsInitial Post: Minimum 200 words excluding references (approximately one (1) page)

Select a health care organization and locate its operating (i.e., utilization rate) and financial data. You may want to use a not-for-profit health care system, as they usually post their annual reports online.Identify one operating indicator (e.g., length of stay, admission, etc.) and two financial performance indicators (e.g., cash and cash equivalents, accounts receivable, accounts payable, short-term loans, etc.).Identify the health care organization you selected, and describe one operating indicator and two financial performance indicators of the organization. Analyze how leaders and managers use these indicators when making decisions about working capital management, capital budgeting, and resource allocation. Support your response by identifying and explaining key points and/or examples presented in the Learning Resources.

In completing Writing Assignment #1 for RGA6207 students will have theopportunity to “reverse translate” an FDA approved product insert and otherdocumentation associated with approval of a pharmaceutical or biologic productback to the information submitted by the manufacturer in Module 1 of an eCTDsubmission. As discussed during Week 3 of the course, the required content for theUS version of Module 1 is described by v2.3.2 of FDA’s Comprehensive Table ofContent Headings (11/1/2018). This document was included in your BlackboardReading Materials folder in Week 3. Specific instructions are as follows:• Search FDA’s available database(s) to identify and select an FDA approvedpharmaceutical or biologic product that received final approval on or afterMay 1, 2017.• Locate the approved product insert, as well as any other regulatorydocumentation associated with the product’s conditional marketing approval• Provide a description of the information that would likely have beensubmitted in the following sections of CTD Module 1, per the instructionsoutlined in v2.3.2 of FDA’s Comprehensive Table of Content Headings(11/11/2018):- 1.14 Labeling- 1.15 Promotional Material- 1.16 Risk Management Plan- 1.17 Post-Marketing Studies- 1.18 Proprietary NamesYour description should summarize the information that you are able toobtain on your conditionally approved product from the FDA website, as wellas from general Internet-based sources. Internet based sources can beparticularly useful to identify promotional materials utilized by productmanufacturers to market the pharmaceutical or biologic product. The FDA’sOffice of Prescription Drug Promotion (OPDP) can often be helpful in thisregard.• From a holistic perspective, please provide an analysis of the riskmanagement issues that might arise from application of FDA pre- and post-market regulations to your product selection. Please include this as part ofyour description of M1 section 1.16.Also, please ensure that your submission includes the following information for yourchosen product1) Date of approval of the product2) A detailed description of the product3) Information regarding any FDA forms used in the marketing of the product4) What competitor versions of the product are available5) A brief synopsis of whether the product chosen is marketed in other globalmarkets (i.e any of the EU5 - Germany, the UK, Italy, France, Spain, Japan,Canada)